Core Viewpoint - Changchun High-tech (000661.SZ) is expected to experience a significant decline in operating performance, with a projected net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of over 90% [1][4]. Group 1: Financial Performance - In 2024, Changchun High-tech's net profit attributable to shareholders decreased by over 40% year-on-year [2]. - For 2025, the company anticipates a net profit drop of 24.33 billion to 23.63 billion yuan compared to the previous year, with a decline rate of 91.48% to 94.19% [4]. - The company reported a net profit of 1.165 billion yuan for the first three quarters of 2025, down 58.23% year-on-year, with total revenue of 9.807 billion yuan, a decrease of 5.60% [4]. Group 2: Factors Influencing Performance - The decline in net profit is attributed to adjustments in pricing and sales policies for core products, particularly long-acting growth hormones, due to their inclusion in the national medical insurance directory [2][6]. - Increased research and development (R&D) expenses, which reached 2.690 billion yuan in 2024, and higher sales expenses have also impacted profitability [10][12]. - The company is focusing on R&D in traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to tumors, respiratory, and immune systems [10]. Group 3: R&D and Product Development - Changchun High-tech's R&D investment for the first three quarters of 2025 was 1.733 billion yuan, a year-on-year increase of 22.91% [12]. - The company has successfully advanced several products, including the GenSci098 injection project, which received a 70 million USD upfront payment [3][14]. - The R&D expenses have been steadily increasing, with a total of 2.690 billion yuan in 2024, representing 19.97% of total revenue [10]. Group 4: Market Position and Future Outlook - The company has historically relied heavily on growth hormones, which have been referred to as its "cash cow" [6]. - The future ability of Changchun High-tech to reduce its dependence on growth hormones is a key concern for investors [15].

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received a clinical trial application acceptance notice from the National Medical Products Administration for the domestically produced drug, GenSci136, intended for the treatment of generalized myasthenia gravis (gMG) [1][4]. Group 1: Drug Information - Product Name: GenSci136, an injectable drug developed by Jinsai Pharmaceutical [1] - Application: Acceptance of clinical trial application for domestic production [1] - Indication: Treatment of generalized myasthenia gravis [1][2] Group 2: Disease Background - gMG is an autoimmune disease characterized by neuromuscular transmission disorders, with a global prevalence of approximately 12.4 per 100,000 people and an incidence rate in China of about 0.68 per 100,000 [2] - Traditional treatments include cholinesterase inhibitors, corticosteroids, and immunosuppressants, but about 20% of patients do not respond well to these therapies [2] Group 3: Drug Mechanism and Research - GenSci136 features a novel drug structure and dual-target mechanism, designed to enhance its blocking activity and prolong its half-life in the body [3] - Non-clinical pharmacology, pharmacokinetics, and toxicology studies indicate that GenSci136 has good efficacy and safety, potentially offering a better treatment option for patients with gMG in China [3] Group 4: Company Impact - Successful progress of the clinical trial application could help the company expand its business structure, optimize product offerings, and enhance its core competitiveness [4]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci136 injection, marking a significant step in the drug registration process [2] Group 1 - The acceptance notice indicates that the clinical trial application for GenSci136 has been officially recognized by regulatory authorities [2] - This development may enhance the company's product pipeline and potential market offerings in the pharmaceutical sector [2] - The approval process reflects the company's commitment to advancing its research and development initiatives [2]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

关于子公司注射用 GenSci136 境内生产药品注册临床试验申请 获得受理的公告 证券代码：000661 证券简称：长春高新 公告编号：2026-008 长春高新技术产业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《受理通知书》，金赛药业注射用 GenSci136 的境内生产 药品注册临床试验申请获得受理，现将有关情况公告如下： 一、药品的基本情况 产品名称：注射用 GenSci136 申请事项：境内生产药品注册临床试验 受理号：CXSL2600163 申请人：长春金赛药业有限责任公司 审批结论：经审查，决定予以受理 比 80%，该病被纳入《第一批罕见病目录》。乙酰胆碱受体（acetylcholine receptor， AChR）抗体是最常见的致病性抗体，影响 AChR 的功能及神经-肌肉接头信号传 递，参与 MG 的发生发展。传统治疗主要包括胆碱酯酶抑制剂、糖皮质激素、 ...

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has had its clinical trial application for the domestically produced injectable GenSci136 accepted by the National Medical Products Administration, marking a significant step in the development of a new treatment for myasthenia gravis [1] Group 1: Product Development - GenSci136 is a Class 1 biological product designed to treat generalized myasthenia gravis, featuring a novel drug structure and a dual-target mechanism of action [1] - The drug aims to provide better treatment options for patients with myasthenia gravis in China [1] Group 2: Business Impact - The progress of this application is expected to broaden the company's business structure and enhance its core competitiveness [1] - The clinical trial process, however, still carries uncertainties that could affect the timeline and outcomes [1]

Group 1 - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance for the clinical trial application of GS3-007a dry suspension from the National Medical Products Administration [1] - GS3-007a is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical, classified as a Class 1 chemical drug, intended for the treatment of idiopathic short stature (ISS) [1] - ISS is a common pediatric endocrine disorder defined as a height below -2 standard deviations (SD) for age, sex, and racial reference values, excluding other causes of short stature [1] Group 2 - The GS3-007a dry suspension offers a daily oral administration option that stimulates endogenous growth hormone release, providing more treatment choices for short children in need of growth promotion [1]

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry mixed suspension, aimed at treating idiopathic short stature (ISS) [1][3]. Group 1: Drug Information - The product GS3-007a is an orally administered small molecule growth hormone secretagogue developed by JinSai Pharmaceutical, classified as a Class 1 chemical drug [1][2]. - The drug is intended for the treatment of idiopathic short stature (ISS), which accounts for approximately 40% of short stature cases in children in China [2]. Group 2: Clinical Trial and Development - GS3-007a has previously been approved for clinical trials related to growth retardation due to endogenous growth hormone deficiency (PGHD), with trials currently ongoing [2]. - The acceptance of the clinical trial application for GS3-007a is expected to facilitate further clinical development and address unmet clinical needs in pediatric growth [3]. Group 3: Company Strategy and Market Position - The development of GS3-007a aligns with the company's strategic focus on pediatric health and growth development products, with no similar products currently available in the domestic market [3]. - The company is committed to advancing the research and development of this project and will fulfill its information disclosure obligations regarding subsequent progress [4].

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a, a drug aimed at treating idiopathic short stature (ISS) [1] Group 1 - Changchun Jinsai Pharmaceutical is responsible for the development of GS3-007a, which is an orally administered small molecule growth hormone secretagogue [1] - The drug is classified as a Class 1 chemical drug in the registration process [1] - The acceptance of the clinical trial application marks a significant step in the drug's development for treating ISS [1]

Mergers and Acquisitions - Changling Hydraulic plans to acquire 12% of the company's shares at an offer price of 35.82 yuan per share [1] - Chip导科技 intends to purchase 100% equity of Jishun Technology for 403 million yuan and 17.15% equity of Shunlei Technology [2] Share Buybacks - Lexin Technology plans to repurchase shares worth between 50 million to 100 million yuan for employee stock ownership or equity incentives [3] - XGIMI Technology intends to repurchase shares worth between 50 million to 100 million yuan [3] - Lingyun Optical plans to change the purpose of 348.08 million shares for repurchase and cancel them [3] - Midea Group has spent 1.998 billion yuan to repurchase 0.35% of its shares [4] - GoerTek has spent 1.108 billion yuan to repurchase 1.14% of its shares [4] External Investments and Daily Operations - Weiyuan Co. has launched a 250,000 tons/year electrolyte solvent project [5] - Far East Co. signed contracts worth 3.075 billion yuan in January through its subsidiary [6] - Changchun Gaoxin's subsidiary GS3-007a has received approval for clinical trial application for a drug [7] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment to provide services to clients [7] - Electric Power Water Power intends to raise funds not exceeding 3.604 billion yuan through acquisition loans [7] - Guoneng Rixin plans to increase investment of 17.625 million yuan in controlling Sanas Zhihui to enhance new energy asset operation service capabilities [7] - Science plans to engage in molybdenum processing and sales to secure a stable resource supply for rhenium recycling [7] - Panlong Pharmaceutical has received approval for clinical trials of the drug Fluorobiphenyl Patch [8] - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan New Energy for 120 million yuan [9] - Daon Co. intends to acquire equity in a Vietnamese company for a total purchase price of approximately 15.737 million USD [10] Performance Changes - Shanghai Yizhong expects a net profit of 64.132 million yuan in 2025, a year-on-year increase of 819.42%, with its core product, injectable paclitaxel polymer micelles, included in the national medical insurance directory [11] - Lianyun Technology anticipates a 20.36% year-on-year increase in net profit in 2025, driven by growth in data storage main control chips [12]